News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG Pays GW Pharmaceuticals $5 Million Upfront for Sativex Rights in Multiple Territories


4/11/2011 7:59:15 AM

LONDON (Dow Jones)--U.K. drug maker GW Pharmaceuticals PLC (GWP.LN) Monday said it has signed a license deal with Novartis AG (NOVN.VX) to commercialize its cannabis-based multiple sclerosis treatment Sativex in a range of markets including Australia, parts of Asia and Africa.

Under the agreement, GW will get an upfront payment of $5 million and receive a further $28.75 million dependent on certain approvals and commercial milestones.

Novartis will have exclusive rights to sell Sativex in Australia; New Zealand; Asia, excluding Japan and China; the Middle East, excluding Israel; and Africa. Regulatory filings for the treatment will be submitted in some of these regions during 2011, GW said.




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES